RAS blockade, hyperkalemia and AKI--look and you will find

Nat Rev Nephrol. 2012 May;8(5):257-8. doi: 10.1038/nrneph.2012.62.

Abstract

Aliskiren combined with other inhibitors of the renin–angiotensin system increases the risk of hyperkalemia. This risk does not translate into an increased incidence of acute kidney injury, suggest the results of a meta-analysis. However, further research is needed to fully evaluate the safety of combination therapy with aliskiren.

MeSH terms

  • Amides / adverse effects*
  • Amides / pharmacology
  • Amides / therapeutic use
  • Angiotensin Receptor Antagonists / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Antihypertensive Agents / adverse effects*
  • Antihypertensive Agents / pharmacology
  • Antihypertensive Agents / therapeutic use
  • Drug Therapy, Combination
  • Fumarates / adverse effects*
  • Fumarates / pharmacology
  • Fumarates / therapeutic use
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Hyperkalemia / chemically induced*
  • Renin / antagonists & inhibitors*
  • Renin-Angiotensin System / drug effects*

Substances

  • Amides
  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antihypertensive Agents
  • Fumarates
  • aliskiren
  • Renin